secwatch.observer — SEC 8-K summary
======================================

Issuer:     Connect Biopharma Holdings Ltd (CNTB)
CIK:        0001835268
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001835268-26-000012
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Connect Biopharma FY2025 net loss $55.5M; cash runway extended by $20.2M placement
--------------------------------------------------------------------------------

- Net loss FY2025 $55.5M ($1.00 per share) vs $15.6M ($0.28 per share) in FY2024.
- Cash and equivalents $44.3M at Dec 31, 2025; with private placement net proceeds, runway into H2 2027.
- Private placement raised $20.2M gross from 6.13M shares at $3.25 each; closed March 31, 2026.
- Phase 1 IV rademikibart showed rapid FEV1 improvement in asthma/COPD; Phase 2 Seabreeze STAT topline data expected mid-2026.
- R&D expense increased to $37.8M (FY2025) from $29.3M due to Phase 2 study initiation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835268/000183526826000012/0001835268-26-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835268/000183526826000012/cntb-20260331.htm
  HTML page:      https://secwatch.observer/filing/0001835268-26-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer